JUN

Summary

JUN (Jun proto-oncogene, AP-1 transcription factor subunit, HGNC:6204) is a protein-coding gene on chromosome 1p32.1, encoding Transcription factor Jun (P05412). Transcription factor that recognizes and binds to the AP-1 consensus motif 5’-TGA[GC]TCA-3’. In precision oncology, JUN Overexpression confers sensitivity to Irbesartan in Colorectal Adenocarcinoma (CIViC Level C). It is a selective cancer dependency (DepMap: 18.8% of cell lines).

This gene is the putative transforming gene of avian sarcoma virus 17. It encodes a protein which is highly similar to the viral protein, and which interacts directly with specific target DNA sequences to regulate gene expression. This gene is intronless and is mapped to 1p32-p31, a chromosomal region involved in both translocations and deletions in human malignancies.

Source: NCBI Gene 3725 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 23 total — 1 pathogenic
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• Precision-oncology evidence (CIViC): 1 curated variant–drug association
• Cancer dependency (DepMap): dependent in 18.8% of screened cell lines
• Transcription factor: yes — 715 downstream targets (CollecTRI)
• MANE Select transcript: NM_002228

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6204
Approved symbol	JUN
Name	Jun proto-oncogene, AP-1 transcription factor subunit
Location	1p32.1
Locus type	gene with protein product
Status	Approved
Aliases	c-Jun, AP-1
Ensembl gene	ENSG00000177606
Ensembl biotype	protein_coding
OMIM	165160
Entrez	3725

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 nonsense_mediated_decay

ENST00000371222, ENST00000678696, ENST00000710273

RefSeq mRNA: 1 — MANE Select: NM_002228 NM_002228

CCDS: CCDS610

Canonical transcript exons

ENST00000371222 — 1 exons

Exon	Start	End
ENSE00001454665	58780791	58784047

Expression profiles

Bgee: expression breadth ubiquitous, 290 present calls, max score 99.72.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 79.8828 / max 3246.6283, expressed in 1814 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
12576	53.9170	1802
12577	14.8868	1709
12575	8.5526	1418
12574	2.1078	841
201526	0.4187	203

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
vena cava	UBERON:0004087	99.72	gold quality
mucosa of stomach	UBERON:0001199	99.66	gold quality
cardia of stomach	UBERON:0001162	99.61	gold quality
mammary duct	UBERON:0001765	99.50	gold quality
saphenous vein	UBERON:0007318	99.50	gold quality
epithelium of mammary gland	UBERON:0003244	99.49	gold quality
seminal vesicle	UBERON:0000998	99.48	gold quality
pericardium	UBERON:0002407	99.37	gold quality
parotid gland	UBERON:0001831	99.28	gold quality
endothelial cell	CL:0000115	99.23	gold quality
pylorus	UBERON:0001166	99.19	gold quality
nipple	UBERON:0002030	99.18	gold quality
urethra	UBERON:0000057	99.09	gold quality
left uterine tube	UBERON:0001303	99.09	gold quality
ventricular zone	UBERON:0003053	99.06	gold quality
trigeminal ganglion	UBERON:0001675	98.96	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.95	gold quality
penis	UBERON:0000989	98.90	gold quality
pancreatic ductal cell	CL:0002079	98.72	gold quality
right ovary	UBERON:0002118	98.71	gold quality
omental fat pad	UBERON:0010414	98.71	gold quality
peritoneum	UBERON:0002358	98.69	gold quality
blood vessel layer	UBERON:0004797	98.65	gold quality
mucosa of paranasal sinus	UBERON:0005030	98.64	gold quality
cervix squamous epithelium	UBERON:0006922	98.62	gold quality
ectocervix	UBERON:0012249	98.60	gold quality
synovial joint	UBERON:0002217	98.51	gold quality
adipose tissue of abdominal region	UBERON:0007808	98.50	gold quality
pharyngeal mucosa	UBERON:0000355	98.47	gold quality
body of stomach	UBERON:0001161	98.42	gold quality

Single-cell (SCXA)

Detected in 43 experiment(s), a significant marker in 32.

Experiment	Marker?	Max mean expression
E-MTAB-9841	yes	9455.45
E-GEOD-137537	yes	6219.91
E-CURD-122	yes	6060.66
E-MTAB-9543	yes	5435.22
E-MTAB-8142	yes	5175.35
E-MTAB-10885	yes	4936.86
E-GEOD-134144	yes	4729.31
E-MTAB-9467	yes	4159.65
E-GEOD-139324	yes	3689.31
E-CURD-53	yes	3209.84
E-HCAD-5	yes	2826.56
E-HCAD-4	yes	2488.78
E-GEOD-106540	yes	1408.48
E-MTAB-7052	yes	1241.42
E-MTAB-7037	yes	1119.79

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

715 targets.

Target	Regulation
A2M
AANAT	Unknown
ABCB1	Activation
ABCC1
ABCC3
ABCC8
ABL1
ACE
ACHE
ACOT11
ACTA1	Unknown
ACTB
ACTG1	Activation
ADAM2
ADARB1
ADCYAP1
ADH7
AFF2
AFP
AGT	Unknown
AKR1B10	Unknown
AKR1B15
AKT1
ALAS2
ALDOA	Activation
ALOX12	Unknown
ANKRD1
AP1	Activation
APC
APOC3	Activation

JASPAR motifs

Motif	Name	Family
MA0099.2	FOS::JUN	Fos-related::Jun-related
MA0099.3	FOS::JUN	Fos-related::Jun-related
MA0099.4	FOS::JUN	Fos-related::Jun-related
MA0462.1	BATF::JUN	B-ATF-related factors::Jun-related
MA0462.2	BATF::JUN	B-ATF-related factors::Jun-related
MA0462.3	BATF::JUN	B-ATF-related factors::Jun-related
MA0488.1	JUN	Jun-related
MA0488.2	JUN	Jun-related
MA0489.1	JUN	Jun-related
MA1126.1	FOS::JUN	Fos-related::Jun-related
MA1126.2	FOS::JUN	Fos-related::Jun-related
MA1127.1	FOSB::JUN	Fos-related::Jun-related
MA1128.1	FOSL1::JUN	Fos-related::Jun-related
MA1128.2	FOSL1::JUN	Fos-related::Jun-related
MA1129.1	FOSL1::JUN	Fos-related::Jun-related
MA1130.1	FOSL2::JUN	Fos-related::Jun-related
MA1130.2	FOSL2::JUN	Fos-related::Jun-related
MA1131.1	FOSL2::JUN	Fos-related::Jun-related
MA1131.2	FOSL2::JUN	Fos-related::Jun-related
MA1132.1	JUN::JUNB	Jun-related
MA1132.2	JUN::JUNB	Jun-related
MA1133.1	JUN::JUNB	Jun-related
MA1133.2	JUN::JUNB	Jun-related

JASPAR matrix evidence (PMIDs): PMID:17916232, PMID:11988758, PMID:22992523, PMID:21703547, PMID:15240010

Upstream regulators (CollecTRI, top): ABL1, AHR, AP1, AR, ARNT, ATF1, ATF2, ATF3, BMAL1, CEBPA, CEBPG, CLOCK, CREB1, CREM, CTCF, CTNNB1, CUX1, E2F1, E2F4, EGR1, EGR2, EGR3, ELK3, ENO1, ERF, ESR1, ESR2, ETS1, FOS, FOXO1, GLI1, GLI2, HDAC3, HDAC4, HES1, HIF1A, HLX, HMGA2, HNF4A, HSF1

miRNA regulators (miRDB)

66 targeting JUN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-139-5P	99.80	69.50	1399
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-3156-3P	99.76	66.72	939
HSA-MIR-8084	99.73	69.57	1760
HSA-MIR-12129	99.72	67.45	1311
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-580-3P	99.67	69.23	1841
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-513C-5P	99.50	68.42	1730

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 18.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury (PMID:11891228)
• Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes (PMID:11891317)
• An alternative model of H ferritin promoter transactivation by c-Jun (H ferritin, also called isoferritin) (PMID:11903046)
• Analysis of heterophilic and homophilic interactions of cadherins using the c-Jun/c-Fos dimerization domains (PMID:11909859)
• Functional role of ERK1/2 activation in phorbol ester-induced promoter activation of human 12(S)-lipoxygenase gene. (PMID:11914583)
• Activation of human monoamine oxidase B gene expression by a protein kinase C MAPK signal transduction pathway involves c-Jun and Egr-1. (PMID:11956220)
• c-Jun associates with the oncoprotein Ski and suppresses Smad2 transcriptional activity (PMID:12034730)
• Kip1 inhibits Jab1 mediated c-Jun dependent transcription (PMID:12119282)
• Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. (PMID:12145210)
• Review.AP1 plays a crucial role during human papillomavirus (HPV) early gene expression, in particular of the expression of E6 and E7 oncoproteins. (PMID:12183893)
• Epstein-Barr virus latent membrane protein 2A may exploit MAPK kinases and affect both the phosphorylation and stability of c-Jun protein (PMID:12186939)
• structurally distinct modes of recognition of the KIX domain of CBP by CREB and this protein (PMID:12437352)
• results suggest strongly that human amylin induces apoptosis in pancreatic islet beta-cells through stimulation of expression and activation of c-Jun (PMID:12441106)
• studies suggest that the cooperative interaction of the estrogen receptor with Fos and Jun proteins helps confer estrogen responsiveness to the endogenous progesterone receptor gene (PMID:12446585)
• Tumor promoter arsenite stimulates histone H3 phosphoacetylation of c-fos and this proto-oncogene chromatin in diploid fibroblasts. (PMID:12547826)
• Phosphorylation of c-jun was induced by TPA only. On the other hand, expression of proto-oncogene c-jun was induced by TPA and Saikosaponin a during 30 min to 6 h of treatment. (PMID:12592382)
• conclude that Ras regulates TNF-alpha-induced chemokine expression by activating the AP-1 pathway and enhancing transcriptional function of NF-kappaB, whereas MEKK1 activates both the AP-1 and NF-kappaB pathways (PMID:12600818)
• AP-1 (c-Jun & FosB) binds to a site in the 5’ untranslated region of the CD95L gene. Transdominant negative Jun mutants reduce CD95L promoter activity. FosB dimerized with c-Jun has an important role in TCR/CD3-mediated activation-induced cell death. (PMID:12618758)
• Critical role of the transcription factor AP-1 for the constitutive and interferon-induced expression of IFI 16. (PMID:12682910)
• data demonstratre that c-Jun physically and functionally interacts with JCV major early regulatory protein large T-Ag and that this interaction modulates JCV transcription and replication in glial cells (PMID:12692226)
• c-Jun has an important functional role in the induction of cell cycle arrest and proliferation arrest of myeloid leukemia cells because of the ligation of the cell surface adhesion receptor CD44 by anti-CD44 antibody. (PMID:12700665)
• The expression of c-Jun protein and c-jun mRNA is significantly increased in the cerebellar vermis of patients with schizophrenia; no significant differences are found in the expression of Jun B or Jun D proteins. (PMID:12799614)
• activator protein 1 and ERKs play crucial roles in FGF2-stimulated premature cranial suture closure (PMID:12815619)
• The AP1 transcription factor c-jun is the prototypical nuclear effector of the JNK signal transduction pathway. (PMID:12853483)
• Data suggest that overexpression and binding of JunB to the AP-1 site may relieve the repression of the core promoter by CD30 in Hodgkin-Redd Sternberg cells, which provide one basis for the constitutive overexpression of CD30 in Hodgkin’s lymphoma (PMID:12875982)
• The Ca2+-mediated increase in AP-1 binding may play an important role in upregulating AP-1-responsive gene expression, in stimulating pulmonary vascular cell proliferation and in pulmonary vascular remodeling in hypoxia-mediated pulmonary hypertension. (PMID:12909593)
• transcription factors Sp1 and c-Jun have roles in regulation of keratin 16 gene expression by epidermal growth factor (PMID:12954631)
• JUN has a role in androgen stimulation which blocks p53-dependent transactivation of the Fas gene, which can be blocked by androgen stimulation during radiation-induced Fas sensitization in prostate cancer cells (PMID:12963547)
• c-Jun fails to act as a negative regulator for the cell survival of pancreatic cancer cells (PMID:12963995)
• Findings strongly suggest that the AP-1/JNK signaling pathway has little or no impact on the generation of inflammatory mediators in neutrophils. (PMID:14500675)
• c-fos and AP-1 are regulated by JNK and p38 MAPK (PMID:14511403)
• NF-kappa B and AP-1 are required for basal MAT2A expression in HepG2 cells and mediate the increase in MAT2A expression in response to TNF-alpha (PMID:14530285)
• 15d-PGJ2 covalently modifies c-Jun and directly inhibits the DNA binding activity of AP-1. In addition, 15d-PGJ2 can promote the oligomerization of a fraction of c-Jun through the formation of intermolecular disulfide bonds or 15d-PGJ2-bonded dimers. (PMID:14532268)
• c-Jun activity is modified by the estrogen receptor in the stress response (PMID:14638681)
• activator protein-1 is repressed by Notch-1 with C promoter-binding factor 1 (PMID:14645224)
• findings demonstrate that activator protein-1 activation in human smooth muscle cells in response to angiotensin II and platelet-derived growth factor-AA is mediated via generation of p22phox-dependent reactive oxygen species (PMID:14652666)
• An inverse correlation between JUN and p27(Kip1) expression levels in breast cancer. (PMID:14654548)
• DET1 promotes ubiquitination and degradation of c-Jun by assembling a multisubunit ubiquitin ligase containing DNA Damage Binding Protein-1 (DDB1), cullin 4A (CUL4A), Regulator of Cullins-1 (ROC1), and constitutively photomorphogenic-1 (PMID:14739464)
• AP1 and CHOP are induced by MEKK3 and have roles in TRAF7-related apoptosis (PMID:15001576)
• Results suggest that in human HL60 cells the presence of the AP-1 signal acts as a survival factor that determines the outcome of myc-induced proliferation or apoptosis. (PMID:15034932)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	jun	ENSDARG00000043531
mus_musculus	Jun	ENSMUSG00000052684
rattus_norvegicus	Jun	ENSRNOG00000026293
drosophila_melanogaster	Jra	FBGN0001291
caenorhabditis_elegans		WBGENE00008945

Paralogs (2): JUND (ENSG00000130522), JUNB (ENSG00000171223)

Protein

Protein identifiers

Transcription factor Jun — P05412 (reviewed: P05412)

Alternative names: Activator protein 1, Proto-oncogene c-Jun, Transcription factor AP-1 subunit Jun, V-jun avian sarcoma virus 17 oncogene homolog, p39

All UniProt accessions (2): A0AA34QVR9, P05412

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor that recognizes and binds to the AP-1 consensus motif 5’-TGA[GC]TCA-3’. Heterodimerizes with proteins of the FOS family to form an AP-1 transcription complex, thereby enhancing its DNA binding activity to the AP-1 consensus sequence 5’-TGA[GC]TCA-3’ and enhancing its transcriptional activity. Together with FOSB, plays a role in activation-induced cell death of T cells by binding to the AP-1 promoter site of FASLG/CD95L, and inducing its transcription in response to activation of the TCR/CD3 signaling pathway. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells. Binds to the USP28 promoter in colorectal cancer (CRC) cells. (Microbial infection) Upon Epstein-Barr virus (EBV) infection, binds to viral BZLF1 Z promoter and activates viral BZLF1 expression.

Subunit / interactions. Heterodimer with either BATF3 or ATF7. Heterodimer with FOS. Heterodimer with FOSB isoform 1 and 2. Component of an AP-1 transcription factor complex composed of JUN-FOS heterodimers. As part of the AP-1 transcription factor complex, forms heterodimers with FOSB, thereby binding to the AP-1 consensus sequence and stimulating transcription. Interacts with FOS and FOSB isoform 1 and 2. The ATF7/JUN heterodimer is essential for ATF7 transactivation activity. Interacts with TSC22D3 (via N-terminus); the interaction inhibits the binding of active AP1 to its target DNA. Interacts with HIVEP3 and MYBBP1A. Interacts with SP1, SPIB and TCF20. Interacts with COPS5; the interaction leads indirectly to its phosphorylation. Component of the SMAD3/SMAD4/JUN/FOS/complex which forms at the AP1 promoter site. The SMAD3/SMAD4 heterodimer acts synergistically with the JUN/FOS heterodimer to activate transcription in response to TGF-beta. Interacts (via its basic DNA binding and leucine zipper domains) with SMAD3 (via an N-terminal domain); the interaction is required for TGF-beta-mediated transactivation of the SMAD3/SMAD4/JUN/FOS/complex. Interacts with methylated RNF187. Binds to HIPK3. Interacts (when phosphorylated) with FBXW7. Found in a complex with PRR7 and FBXW7. Interacts with PRR7 and FBXW7; the interaction inhibits ubiquitination-mediated JUN degradation promoting its phosphorylation and transcriptional activity. Interacts with RBM39. Interacts with PAGE4. Interacts with ARK2N and CSNK2B; the interaction with ARK2N is mediated by CSNK2B.

Subcellular location. Nucleus.

Tissue specificity. Expressed in the developing and adult prostate and prostate cancer cells.

Post-translational modifications. Ubiquitinated by the SCF(FBXW7), leading to its degradation. Ubiquitination takes place following phosphorylation, that promotes interaction with FBXW7. Phosphorylated by CaMK4 and PRKDC; phosphorylation enhances the transcriptional activity. Phosphorylated by HIPK3. Phosphorylated by DYRK2 at Ser-243; this primes the protein for subsequent phosphorylation by GSK3B at Thr-239. Phosphorylated at Thr-239, Ser-243 and Ser-249 by GSK3B; phosphorylation reduces its ability to bind DNA. Phosphorylated by PAK2 at Thr-2, Thr-8, Thr-89, Thr-93 and Thr-286 thereby promoting JUN-mediated cell proliferation and transformation. Phosphorylated by PLK3 following hypoxia or UV irradiation, leading to increase DNA-binding activity. Phosphorylated by VRK1. Acetylated at Lys-271 by EP300.

Similarity. Belongs to the bZIP family. Jun subfamily.

RefSeq proteins (1): NP_002219* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002112	Leuzip_Jun	Family
IPR004827	bZIP	Domain
IPR005643	JNK	Domain
IPR008917	TF_DNA-bd_sf	Homologous_superfamily
IPR046347	bZIP_sf	Homologous_superfamily
IPR050946	AP-1_TF_bZIP	Family

Pfam: PF00170, PF03957

UniProt features (43 total): modified residue 14, mutagenesis site 12, cross-link 5, sequence conflict 4, region of interest 3, chain 1, domain 1, sequence variant 1, helix 1, site 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
6Y3V	X-RAY DIFFRACTION	1.5
5T01	X-RAY DIFFRACTION	1.89
5FV8	X-RAY DIFFRACTION	1.99
1JNM	X-RAY DIFFRACTION	2.2
8SOS	X-RAY DIFFRACTION	2.33
1A02	X-RAY DIFFRACTION	2.7
1T2K	X-RAY DIFFRACTION	3
1FOS	X-RAY DIFFRACTION	3.05
1S9K	X-RAY DIFFRACTION	3.1
1JUN	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P05412-F1	62.45	0.22

Antibody-complex structures (SAbDab): 1 — 8SOS

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 272 (necessary for synergistic transcriptional activity with smad3)

Post-translational modifications (19): 63, 73, 89, 91, 93, 239, 243, 249, 271, 286, 35, 50, 56, 70, 226, 2, 8, 56, 58

Mutagenesis-validated functional residues (12):

Position	Phenotype
2	complete loss of pak2-mediated phosphorylation; when associated with a-8; a-89; a-93; and a-286.
6–194	abolishes activation of faslg/cd95l transcription.
8	complete loss of pak2-mediated phosphorylation; when associated with a-2; a-89; a-93; and a-286.
63	greatly reduced atf7-mediated transcriptional activity; when associated with a-73. abolishes interaction with fbxw7; whe
73	greatly reduced atf7-mediated transcriptional activity; when associated with a-63. abolishes interaction with fbxw7; whe
89	complete loss of pak2-mediated phosphorylation; when associated with a-2; a-8; a-93; and a-286.
91	abolishes interaction with fbxw7; when associated with a-63; a-73 and a-93.
93	abolishes interaction with fbxw7; when associated with a-63; a-73 and a-91.
93	complete loss of pak2-mediated phosphorylation; when associated with a-2; a-8; a-89; and a-286.
243	abolishes phosphorylation by dyrk2. abolishes phosphorylation by gsk3b at thr-239.
272	abolishes the synergistic activity with smad3 to activate tgf-beta-mediated transcription.
286	complete loss of pak2-mediated phosphorylation; when associated with a-2; a-8; a-89; and a-93.

Function

Pathways and Gene Ontology

Reactome pathways

67 pathways

ID	Pathway
R-HSA-1912408	Pre-NOTCH Transcription and Translation
R-HSA-2559580	Oxidative Stress Induced Senescence
R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)
R-HSA-2871796	FCERI mediated MAPK activation
R-HSA-450341	Activation of the AP-1 family of transcription factors
R-HSA-5617472	Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-5687128	MAPK6/MAPK4 signaling
R-HSA-6796648	TP53 Regulates Transcription of DNA Repair Genes
R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models
R-HSA-8943724	Regulation of PTEN gene transcription
R-HSA-9018519	Estrogen-dependent gene expression
R-HSA-9673324	WNT5:FZD7-mediated leishmania damping
R-HSA-9725370	Signaling by ALK fusions and activated point mutants
R-HSA-9909649	Regulation of PD-L1(CD274) transcription
R-HSA-9976102	Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)
R-HSA-1257604	PIP3 activates AKT signaling
R-HSA-1266738	Developmental Biology
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-157118	Signaling by NOTCH
R-HSA-162582	Signal Transduction
R-HSA-1643685	Disease
R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade
R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane
R-HSA-166166	MyD88-independent TLR4 cascade
R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade
R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade
R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade
R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade

MSigDB gene sets: 938 (showing top): PID_BCR_5PATHWAY, GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, GSE45365_NK_CELL_VS_CD8_TCELL_DN, GOBP_MYELOID_CELL_DIFFERENTIATION, GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_UP, GOBP_SMAD_PROTEIN_SIGNAL_TRANSDUCTION, REACTOME_SIGNALING_BY_NOTCH, GOBP_NEGATIVE_REGULATION_OF_NEURON_APOPTOTIC_PROCESS, GOBP_HEPATICOBILIARY_SYSTEM_DEVELOPMENT, GOBP_EPITHELIUM_DEVELOPMENT, REACTOME_INNATE_IMMUNE_SYSTEM, BENPORATH_ES_WITH_H3K27ME3, GRUETZMANN_PANCREATIC_CANCER_DN, PID_TELOMERASE_PATHWAY, HARRIS_HYPOXIA

GO Biological Process (43): negative regulation of transcription by RNA polymerase II (GO:0000122), angiogenesis (GO:0001525), microglial cell activation (GO:0001774), liver development (GO:0001889), positive regulation of endothelial cell proliferation (GO:0001938), outflow tract morphogenesis (GO:0003151), regulation of transcription by RNA polymerase II (GO:0006357), apoptotic process (GO:0006915), transforming growth factor beta receptor signaling pathway (GO:0007179), JNK cascade (GO:0007254), cell population proliferation (GO:0008283), negative regulation of cell population proliferation (GO:0008285), response to xenobiotic stimulus (GO:0009410), positive regulation of epithelial cell migration (GO:0010634), release from viral latency (GO:0019046), monocyte differentiation (GO:0030224), axon regeneration (GO:0031103), response to endoplasmic reticulum stress (GO:0034976), leading edge cell differentiation (GO:0035026), response to muscle stretch (GO:0035994), regulation of cell population proliferation (GO:0042127), negative regulation of DNA binding (GO:0043392), negative regulation of neuron apoptotic process (GO:0043524), host-mediated suppression of viral transcription (GO:0043922), host-mediated activation of viral transcription (GO:0043923), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), positive regulation of fibroblast proliferation (GO:0048146), response to steroid hormone (GO:0048545), regulation of cell cycle (GO:0051726), SMAD protein signal transduction (GO:0060395), eyelid development in camera-type eye (GO:0061029), positive regulation of ERK1 and ERK2 cascade (GO:0070374), cellular response to calcium ion (GO:0071277), cellular response to anisomycin (GO:0072740), integrated stress response signaling (GO:0140467), positive regulation of miRNA transcription (GO:1902895), positive regulation of vascular associated smooth muscle cell proliferation (GO:1904707), positive regulation of DNA-templated transcription initiation (GO:2000144)

GO Molecular Function (21): transcription cis-regulatory region binding (GO:0000976), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA binding (GO:0003677), chromatin binding (GO:0003682), DNA-binding transcription factor activity (GO:0003700), RNA binding (GO:0003723), GTPase activator activity (GO:0005096), enzyme binding (GO:0019899), ubiquitin protein ligase binding (GO:0031625), cAMP response element binding (GO:0035497), identical protein binding (GO:0042802), ubiquitin-like protein ligase binding (GO:0044389), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629), R-SMAD binding (GO:0070412), general transcription initiation factor binding (GO:0140296), sequence-specific double-stranded DNA binding (GO:1990837), double-stranded DNA binding (GO:0003690), protein binding (GO:0005515)

GO Cellular Component (9): nuclear chromosome (GO:0000228), chromatin (GO:0000785), euchromatin (GO:0000791), nucleus (GO:0005634), nucleoplasm (GO:0005654), transcription regulator complex (GO:0005667), transcription repressor complex (GO:0017053), transcription factor AP-1 complex (GO:0035976), RNA polymerase II transcription regulator complex (GO:0090575)

Reactome top-level categories

Rollup of top-17 pathways:

Category	Pathways
Cellular Senescence	2
Pre-NOTCH Expression and Processing	1
Fc epsilon receptor (FCERI) signaling	1
MAPK targets/ Nuclear events mediated by MAP kinases	1
Activation of HOX genes during differentiation	1
MAPK family signaling cascades	1
Transcriptional Regulation by TP53	1
Neurodegenerative Diseases	1
PTEN Regulation	1
ESR-mediated signaling	1
Killing mechanisms	1
Signaling by ALK in cancer	1
Regulation of PD-L1(CD274) expression	1
Differentiation of T cells	1
Intracellular signaling by second messengers	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	4
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
regulation of DNA-templated transcription	2
chromatin	2
DNA-binding transcription factor activity, RNA polymerase II-specific	2
nucleic acid binding	2
protein binding	2
chromosome	2
nuclear lumen	2
cellular anatomical structure	2
transcription regulator complex	2
negative regulation of DNA-templated transcription	1
blood vessel morphogenesis	1
anatomical structure formation involved in morphogenesis	1
leukocyte activation involved in inflammatory response	1
macrophage activation	1
glial cell activation	1
gland development	1
hepaticobiliary system development	1
endothelial cell proliferation	1
regulation of endothelial cell proliferation	1
positive regulation of epithelial cell proliferation	1
heart morphogenesis	1
anatomical structure morphogenesis	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cellular response to transforming growth factor beta stimulus	1
transforming growth factor beta receptor superfamily signaling pathway	1
MAPK cascade	1
cellular process	1
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
response to chemical	1
epithelial cell migration	1
regulation of epithelial cell migration	1
positive regulation of cell migration	1
viral process	1

Protein interactions and networks

STRING

10838 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
JUN	FOSL2	P15408	999
JUN	FOS	P01100	999
JUN	FOSB	P53539	998
JUN	CREB1	P16220	997
JUN	FOSL1	P15407	996
JUN	ATF3	P18847	996
JUN	COPS5	Q92905	995
JUN	ESR1	P03372	995
JUN	STAT3	P40763	994
JUN	BATF	Q16520	993
JUN	MAF	O75444	993
JUN	NFKB1	P19838	992
JUN	EP300	Q09472	992
JUN	TP53	P04637	992
JUN	IRF3	Q14653	992

IntAct

464 interactions, top by confidence:

A	B	Type	Score
JUN	FOS	psi-mi:“MI:2364”(proximity)	0.980
JUN	FOS	psi-mi:“MI:0407”(direct interaction)	0.980
FOS	JUN	psi-mi:“MI:0914”(association)	0.980
FOS	JUN	psi-mi:“MI:0407”(direct interaction)	0.980
FOS	JUN	psi-mi:“MI:2364”(proximity)	0.980
JUN	FOS	psi-mi:“MI:0915”(physical association)	0.980
ATF2	JUN	psi-mi:“MI:0407”(direct interaction)	0.950
JUN	ATF2	psi-mi:“MI:0407”(direct interaction)	0.950
JUN	ATF2	psi-mi:“MI:0914”(association)	0.950
ATF2	JUN	psi-mi:“MI:0914”(association)	0.950
JUN	ATF2	psi-mi:“MI:0915”(physical association)	0.950
JUN	FOSL2	psi-mi:“MI:0407”(direct interaction)	0.930
FOSL2	JUN	psi-mi:“MI:0407”(direct interaction)	0.930
JUN	FOSL2	psi-mi:“MI:0915”(physical association)	0.930
JUN	BATF3	psi-mi:“MI:0407”(direct interaction)	0.870
BATF3	JUN	psi-mi:“MI:0407”(direct interaction)	0.870
JUN	FOSL1	psi-mi:“MI:2364”(proximity)	0.850
JUN	ATF3	psi-mi:“MI:0407”(direct interaction)	0.850
MAPK8	JUN	psi-mi:“MI:0407”(direct interaction)	0.850
FOSL1	JUN	psi-mi:“MI:0914”(association)	0.850
JUN	MAPK8	psi-mi:“MI:0217”(phosphorylation reaction)	0.850
MAPK10	JUN	psi-mi:“MI:0407”(direct interaction)	0.760
MAPK10	JUN	psi-mi:“MI:0217”(phosphorylation reaction)	0.760
JUN	JUN	psi-mi:“MI:0407”(direct interaction)	0.740

BioGRID (926): JUN (Biochemical Activity), JUN (Biochemical Activity), JUN (Affinity Capture-Western), JUN (Biochemical Activity), JUN (Biochemical Activity), PPP3CA (Affinity Capture-Western), PPP3CA (Reconstituted Complex), SP1 (Reconstituted Complex), SP1 (Affinity Capture-Western), JUN (Affinity Capture-Western), JUN (Affinity Capture-Western), JUN (Reconstituted Complex), JUN (Affinity Capture-Western), JUN (Co-fractionation), JUN (Co-localization)

ESM2 similar proteins: A0JMF8, A2RSY1, A6QLW9, B1WAV2, B2GV50, O60271, O75069, O77627, P05412, P05627, P0C090, P17325, P22670, P48377, P48378, P48379, P48380, P48381, P56432, Q0V989, Q0V9K5, Q16656, Q32NR3, Q3KR73, Q499B3, Q49GP3, Q4R3I8, Q4R3Z4, Q4V872, Q4VGL6, Q58A65, Q5EAP5, Q5EY87, Q5RDR2, Q5RJA1, Q5TC82, Q62739, Q66IV1, Q6NRE7, Q6NUC6

Diamond homologs: A0A0A2J9B3, A7YY54, B8NLU5, O77627, O93602, P05411, P05412, P05627, P09450, P11939, P12981, P15066, P15336, P16951, P17275, P17325, P17535, P17544, P18870, P23050, P24898, P27921, P52890, P52909, P54864, P56432, P78962, P79703, Q00969, Q02100, Q02930, Q09771, Q09926, Q0VBZ5, Q2U616, Q4WVQ7, Q59VR1, Q5R9C9, Q8K1L0, Q8R0S1

SIGNOR signaling

129 interactions.

A	Effect	B	Mechanism
PELI3	up-regulates	JUN
VRK1	up-regulates	JUN	phosphorylation
JUN	up-regulates	TCF4	binding
GSK3A	down-regulates	JUN	phosphorylation
PP2B	up-regulates	JUN	dephosphorylation
PLK3	up-regulates	JUN	phosphorylation
RELA	up-regulates	JUN	binding
MAPK10	up-regulates	JUN	phosphorylation
PAK2	up-regulates	JUN	phosphorylation
DVL1	up-regulates	JUN	binding
CDK3	up-regulates	JUN	phosphorylation
MAPK9	up-regulates	JUN	phosphorylation
(-)-anisomycin	up-regulates	JUN	“chemical activation”
DYRK2	down-regulates	JUN	phosphorylation
CSNK2A1	down-regulates	JUN	phosphorylation
JUN	up-regulates	Brown_adipogenesis
MAPK1	“up-regulates activity”	JUN	phosphorylation
NfKb-p65/p50	up-regulates	JUN	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 104 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
MAPK targets/ Nuclear events mediated by MAP kinases	6	44.1×	1e-06
NGF-stimulated transcription	7	27.0×	1e-06
MAP kinase activation	6	25.0×	6e-06
FCERI mediated MAPK activation	5	23.4×	5e-05
Interleukin-17 signaling	6	20.6×	1e-05
Toll Like Receptor 10 (TLR10) Cascade	7	20.4×	5e-06
Toll Like Receptor 5 (TLR5) Cascade	7	20.4×	5e-06
MyD88 cascade initiated on plasma membrane	7	19.3×	6e-06

GO biological processes:

GO term	Partners	Fold	FDR
integrated stress response signaling	7	53.4×	2e-08
osteoclast differentiation	5	18.7×	1e-03
positive regulation of gene expression	12	5.0×	9e-04

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

23 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	20
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1706623	NM_002228.4(JUN):c.659del (p.Pro220fs)	Pathogenic

SpliceAI

41 predictions. Top by Δscore:

Variant	Effect	Δscore
1:58783059:CTT:C	acceptor_gain	0.7600
1:58783060:TTT:T	acceptor_gain	0.7600
1:58783893:TCTGG:T	acceptor_gain	0.5200
1:58783902:T:TC	acceptor_gain	0.4700
1:58783913:G:GC	acceptor_gain	0.4700
1:58783006:T:TG	acceptor_gain	0.4600
1:58783061:T:G	acceptor_gain	0.4600
1:58783913:G:C	acceptor_gain	0.4400
1:58783061:T:C	acceptor_gain	0.3800
1:58783894:C:CC	acceptor_gain	0.3300
1:58783895:TGG:T	acceptor_gain	0.3300
1:58783896:GGG:G	acceptor_gain	0.3300
1:58783900:A:T	acceptor_gain	0.3300
1:58783891:GCTC:G	acceptor_gain	0.3100
1:58783894:C:G	acceptor_gain	0.3100
1:58783892:CT:C	acceptor_gain	0.3000
1:58783902:T:C	acceptor_gain	0.2900
1:58783931:TTGC:T	acceptor_gain	0.2800
1:58783588:T:TA	donor_gain	0.2700
1:58783897:GGC:G	acceptor_gain	0.2500
1:58783901:GTT:G	acceptor_gain	0.2500
1:58783892:CTCT:C	acceptor_gain	0.2400
1:58783933:G:GT	acceptor_gain	0.2400
1:58783938:TCGG:T	acceptor_gain	0.2400
1:58783890:AGCTC:A	acceptor_gain	0.2300
1:58783899:CAGT:C	acceptor_gain	0.2300
1:58783889:TAGCT:T	acceptor_loss	0.2200
1:58783892:CTC:C	acceptor_loss	0.2200
1:58783893:TCT:T	acceptor_loss	0.2200
1:58783894:CTGG:C	acceptor_loss	0.2200

AlphaMissense

2166 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:58782106:A:G	L322P	1.000
1:58782106:A:T	L322H	1.000
1:58782111:G:C	C320W	1.000
1:58782112:C:A	C320F	1.000
1:58782112:C:G	C320S	1.000
1:58782112:C:T	C320Y	1.000
1:58782113:A:G	C320R	1.000
1:58782113:A:T	C320S	1.000
1:58782115:C:A	G319V	1.000
1:58782115:C:T	G319E	1.000
1:58782116:C:A	G319W	1.000
1:58782116:C:G	G319R	1.000
1:58782116:C:T	G319R	1.000
1:58782124:A:T	V316D	1.000
1:58782126:G:C	H315Q	1.000
1:58782126:G:T	H315Q	1.000
1:58782127:T:A	H315L	1.000
1:58782127:T:C	H315R	1.000
1:58782127:T:G	H315P	1.000
1:58782128:G:A	H315Y	1.000
1:58782128:G:C	H315D	1.000
1:58782128:G:T	H315N	1.000
1:58782136:A:G	V312A	1.000
1:58782136:A:T	V312D	1.000
1:58782137:C:A	V312F	1.000
1:58782142:T:G	Q310P	1.000
1:58782144:T:A	K309N	1.000
1:58782144:T:G	K309N	1.000
1:58782145:T:A	K309I	1.000
1:58782146:T:C	K309E	1.000

dbSNP variants (sampled 300 via entrez): RS1000134509 (1:58784735 C>A,T), RS1002236220 (1:58781981 T>C), RS1002522831 (1:58783476 C>G,T), RS1002553932 (1:58783248 C>T), RS1002673759 (1:58781801 A>G,T), RS1002685861 (1:58783474 C>G,T), RS1003231149 (1:58783666 G>A), RS1004097773 (1:58781904 T>G), RS1004199037 (1:58781293 G>A), RS1004415465 (1:58781834 A>G), RS1004536812 (1:58782991 C>A,T), RS1004757670 (1:58783226 C>T), RS1006088100 (1:58783411 C>A,T), RS1006143902 (1:58784143 G>T), RS1006521447 (1:58785303 C>T)

Disease associations

OMIM: gene MIM:165160 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast neoplasm (MONDO:0021100)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST000477_4	Cognitive performance	5.000000e-06
GCST003542_175	Night sleep phenotypes	8.000000e-06
GCST90011899_102	Aspartate aminotransferase levels	2.000000e-10

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0003926	neuropsychological test
EFO:0004736	aspartate aminotransferase measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001943	Breast Neoplasms	C04.588.180; C17.800.090.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2111421 (PROTEIN COMPLEX), CHEMBL4977 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 94,323 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL140	CURCUMIN	3	93,882
CHEMBL17205	CYCLOVALONE	2	348
CHEMBL129857	AS-602868	1	93

Clinical evidence (CIViC)

Drug × variant × indication: 1 predictive associations from 1 curated evidence items.

Variant	Therapy	Indication	Effect	Level	CIViC
JUN Overexpression	Irbesartan	Colorectal Adenocarcinoma	Sensitivity/Response	CIViC C	EID1633

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

9 measured of 9 human assays (9 total across all organisms); most potent 9 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(1E,4E)-1,5-dipyridin-3-ylpenta-1,4-dien-3-one	IC50	3400 nM	US-9187397: Therapeutic curcumin derivatives
(1E,4E)-1,5-dipyridin-4-ylpenta-1,4-dien-3-one	IC50	3500 nM	US-9187397: Therapeutic curcumin derivatives
(1E,4E)-1,5-bis(2-hydroxyphenyl)penta-1,4-dien-3-one	IC50	4200 nM	US-9187397: Therapeutic curcumin derivatives
2,6-Bis-[1-(4-hydroxy-3-methoxy-phenyl)-meth-(E)-ylidene]-cyclohexanone	IC50	4200 nM	US-9187397: Therapeutic curcumin derivatives
[4-[(1E,4E)-5-(4-acetyloxy-3-methoxyphenyl)-3-oxopenta-1,4-dienyl]-2-methoxyphenyl] acetate	IC50	5400 nM	US-9187397: Therapeutic curcumin derivatives
(1E,4E)-1,5-bis(2,5-dimethoxyphenyl)penta-1,4-dien-3-one	IC50	6400 nM	US-9187397: Therapeutic curcumin derivatives
(1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-4-methylhepta-1,4,6-trien-3-one	IC50	6700 nM	US-9187397: Therapeutic curcumin derivatives
(1E,4Z,6E)-4-benzyl-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one	IC50	7600 nM	US-9187397: Therapeutic curcumin derivatives
(1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one	IC50	8200 nM	US-9187397: Therapeutic curcumin derivatives

ChEMBL bioactivities

190 potent at pChembl≥5 of 210 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.52	IC50	3	nM	CHEMBL337665
8.16	IC50	6.9	nM	CURCUMIN
8.10	IC50	8	nM	AS-602868
8.10	IC50	7.9	nM	NORDIHYDROGUAIARETIC ACID
7.70	IC50	20	nM	CHEMBL132495
7.70	IC50	20	nM	CHEMBL43549
7.70	IC50	20	nM	CHEMBL1761563
7.50	IC50	32	nM	AILANTHINONE
7.46	IC50	35	nM	CHEMBL85822
7.40	IC50	40	nM	GLAUCARUBINONE
7.40	IC50	40	nM	CHEMBL1761561
7.40	IC50	40	nM	CHEMBL1761582
7.40	IC50	40	nM	CHEMBL1761583
7.35	IC50	45	nM	CHEMBL86615
7.30	IC50	50	nM	CHEMBL336546
7.30	IC50	50	nM	CHEMBL1761584
7.19	IC50	65	nM	TYLOPHORINIDINE
7.17	IC50	68	nM	CHEMBL250474
7.15	IC50	71	nM	CHEMBL564009
7.01	IC50	98	nM	CHEMBL315804
7.00	IC50	100	nM	CHEMBL131006
7.00	IC50	100	nM	CHEMBL42952
7.00	IC50	100	nM	CHEMBL3341912
7.00	IC50	100	nM	CHEMBL1761577
7.00	IC50	100	nM	CHEMBL43610
6.96	IC50	110	nM	TYLOPHORININE
6.92	IC50	120	nM	CHEMBL1761555
6.89	EC50	130	nM	NOTHOSPONDIN
6.89	IC50	130	nM	CHEMBL1761581
6.89	EC50	130	nM	GLAUCARUBINONE
6.80	IC50	160	nM	CHEMBL1761579
6.70	IC50	200	nM	CHEMBL340779
6.70	IC50	200	nM	CHEMBL1761569
6.70	IC50	200	nM	CHEMBL44525
6.70	IC50	200	nM	CHEMBL295192
6.70	IC50	200	nM	CHEMBL295508
6.70	IC50	200	nM	CHEMBL42650
6.70	IC50	200	nM	CHEMBL43534
6.68	IC50	210	nM	CHEMBL87274
6.68	IC50	210	nM	DIHYDROGUAIARETIC ACID
6.60	IC50	250	nM	CHEMBL1761565
6.54	IC50	290	nM	CHEMBL1761562
6.52	IC50	300	nM	CHEMBL339462
6.52	IC50	300	nM	CHEMBL337656
6.52	IC50	300	nM	CHEMBL87433
6.52	IC50	300	nM	CHEMBL296695
6.52	IC50	300	nM	CHEMBL45261
6.52	IC50	300	nM	CHEMBL296202
6.52	IC50	300	nM	CHEMBL43259
6.52	IC50	300	nM	CHEMBL42204

PubChem BioAssay actives

184 with measured affinity, of 540 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[(1S,4S,5R,6R,7S,8R,11R,13S,17S,18S,19R)-4,5,17-trihydroxy-6,14,18-trimethyl-9,16-dioxo-3,10-dioxapentacyclo[9.8.0.01,7.04,19.013,18]nonadec-14-en-8-yl] acetate	422099: Inhibition of TPA-induced AP1 transfected in HEK293 cells assessed as inhibition of beta-lactamase reporter activity treated 1 hr before TPA stimulation measured after 18 hrs by luciferase reporter gene assay	ic50	<0.0001	uM
methyl (1S,2R,3R,4S,5R,8R,9S,10R,13R,15S,16S)-10-acetyloxy-3,4-dihydroxy-1,16-dimethyl-11,19-dioxo-6,12,20-trioxahexacyclo[13.7.0.02,8.05,9.08,13.017,21]docosa-17,21-diene-5-carboxylate	422099: Inhibition of TPA-induced AP1 transfected in HEK293 cells assessed as inhibition of beta-lactamase reporter activity treated 1 hr before TPA stimulation measured after 18 hrs by luciferase reporter gene assay	ic50	<0.0001	uM
[(1S,4S,5R,7S,8R,11R,13S,17S,18S,19R)-4,5,17-trihydroxy-14,18-dimethyl-6-methylidene-9,16-dioxo-3,10-dioxapentacyclo[9.8.0.01,7.04,19.013,18]nonadec-14-en-8-yl] (E)-dodec-3-enoate	422099: Inhibition of TPA-induced AP1 transfected in HEK293 cells assessed as inhibition of beta-lactamase reporter activity treated 1 hr before TPA stimulation measured after 18 hrs by luciferase reporter gene assay	ic50	<0.0001	uM
methyl (1R,2S,3R,6R,8R,13S,14R,15R,16S,17S)-3-[(E)-3,4-dimethylpent-2-enoyl]oxy-10,15,16-trihydroxy-9,13-dimethyl-4,11-dioxo-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-9-ene-17-carboxylate	422099: Inhibition of TPA-induced AP1 transfected in HEK293 cells assessed as inhibition of beta-lactamase reporter activity treated 1 hr before TPA stimulation measured after 18 hrs by luciferase reporter gene assay	ic50	<0.0001	uM
1-[(6-methoxy-2-thiophen-2-ylquinazolin-4-yl)amino]-3-methylpyrrole-2,5-dione	1178333: Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	ic50	0.0030	uM
4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol	1178344: Inhibition of Fos-Jun dimer formation (unknown origin)	ic50	0.0079	uM
1-[(5-methoxy-2-thiophen-2-ylquinazolin-4-yl)amino]-3-methylpyrrole-2,5-dione	1178333: Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	ic50	0.0080	uM
N-[3,5-bis(trifluoromethyl)phenyl]-2-chloro-4-methylpyrimidine-5-carboxamide	1178333: Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	ic50	0.0200	uM
8-(6-methyl-3-pyridinyl)-N-[4-(3-morpholin-4-yl-1,2,4-triazol-1-yl)phenyl]quinazolin-2-amine	589356: Inhibition of c-Jun	ic50	0.0200	uM
ethyl 4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-thiophen-2-ylpyrimidine-5-carboxylate	1178333: Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	ic50	0.0200	uM
[(1S,4S,5R,6R,7S,8R,11R,13S,17S,18S,19R)-4,5,17-trihydroxy-6,14,18-trimethyl-9,16-dioxo-3,10-dioxapentacyclo[9.8.0.01,7.04,19.013,18]nonadec-14-en-8-yl] 2-methylbutanoate	422099: Inhibition of TPA-induced AP1 transfected in HEK293 cells assessed as inhibition of beta-lactamase reporter activity treated 1 hr before TPA stimulation measured after 18 hrs by luciferase reporter gene assay	ic50	0.0320	uM
ethyl 4-ethyl-2-[methyl-(3-methyl-2,5-dioxopyrrol-1-yl)amino]pyrimidine-5-carboxylate	1178333: Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	ic50	0.0350	uM
[(1S,4R,5R,6R,7S,8R,11R,13S,17S,18S,19R)-4,5,17-trihydroxy-6,14,18-trimethyl-9,16-dioxo-3,10-dioxapentacyclo[9.8.0.01,7.04,19.013,18]nonadec-14-en-8-yl] (2S)-2-hydroxy-2-methylbutanoate	422099: Inhibition of TPA-induced AP1 transfected in HEK293 cells assessed as inhibition of beta-lactamase reporter activity treated 1 hr before TPA stimulation measured after 18 hrs by luciferase reporter gene assay	ic50	0.0400	uM
7,8-bis(1-methylpyrazol-4-yl)-N-[4-(3-morpholin-4-yl-1,2,4-triazol-1-yl)phenyl]quinazolin-2-amine	589356: Inhibition of c-Jun	ic50	0.0400	uM
7-(1-methylpyrazol-4-yl)-N-[4-(3-morpholin-4-yl-1,2,4-triazol-1-yl)phenyl]-8-phenylquinazolin-2-amine	589356: Inhibition of c-Jun	ic50	0.0400	uM
N-[4-[3-(6-methyl-3-pyridinyl)-1,2,4-triazol-1-yl]phenyl]-7-(1H-pyrazol-4-yl)quinazolin-2-amine	589356: Inhibition of c-Jun	ic50	0.0400	uM
ethyl 2-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-4-(5-methylthiophen-2-yl)pyrimidine-5-carboxylate	1178333: Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	ic50	0.0450	uM
8-methoxy-7-(1-methylpyrazol-4-yl)-N-[4-(3-morpholin-4-yl-1,2,4-triazol-1-yl)phenyl]quinazolin-2-amine	589356: Inhibition of c-Jun	ic50	0.0500	uM
N-[3,5-bis(trifluoromethyl)phenyl]-2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxamide	1178333: Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	ic50	0.0500	uM
(13aS,14S)-3,7-dimethoxy-9,11,12,13,13a,14-hexahydrophenanthro[10,9-f]indolizine-6,14-diol	308180: Inhibition of AP1-mediated gene transcription in HepG2 cells by luciferase reporter gene assay	ic50	0.0650	uM
(13aR)-3,7-dimethoxy-9,11,12,13,13a,14-hexahydrophenanthro[10,9-f]indolizin-6-ol	308180: Inhibition of AP1-mediated gene transcription in HepG2 cells by luciferase reporter gene assay	ic50	0.0680	uM
[(1S,4S,5R,6R,7S,11S,12R,13S,16S,17S,18S,19R)-4,5,16,17-tetrahydroxy-6,14,18-trimethyl-9-oxo-3,10-dioxapentacyclo[9.8.0.01,7.04,19.013,18]nonadec-14-en-12-yl] 3-methylbut-2-enoate	422099: Inhibition of TPA-induced AP1 transfected in HEK293 cells assessed as inhibition of beta-lactamase reporter activity treated 1 hr before TPA stimulation measured after 18 hrs by luciferase reporter gene assay	ic50	0.0710	uM
1-[[5-benzoyl-4-(trifluoromethyl)pyrimidin-2-yl]amino]-3-methylpyrrole-2,5-dione	1178333: Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	ic50	0.0980	uM
2-chloro-8-(trifluoromethyl)-6H-pyrimido[4,5-b][1,5]benzothiazepin-5-one	1178333: Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	ic50	0.1000	uM
N-[3,5-bis(trifluoromethyl)phenyl]-2-fluoro-4-(trifluoromethyl)pyrimidine-5-carboxamide	1178333: Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	ic50	0.1000	uM
ethyl 4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-phenylpyrimidine-5-carboxylate	1178333: Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	ic50	0.1000	uM
ethyl 4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-thiophen-3-ylpyrimidine-5-carboxylate	95092: Inhibition of AP-1 (activator protein-1) mediated transcriptional activation in Jurkat T-cells	ic50	0.1000	uM
8-chloro-7-(1-methylpyrazol-4-yl)-N-[4-(3-morpholin-4-yl-1,2,4-triazol-1-yl)phenyl]quinazolin-2-amine	589356: Inhibition of c-Jun	ic50	0.1000	uM
(13aS,14R)-3,6,7-trimethoxy-9,11,12,13,13a,14-hexahydrophenanthro[9,10-f]indolizin-14-ol	308180: Inhibition of AP1-mediated gene transcription in HepG2 cells by luciferase reporter gene assay	ic50	0.1100	uM
N-[4-(3-morpholin-4-yl-1,2,4-triazol-1-yl)phenyl]-7-(1H-pyrazol-4-yl)quinazolin-2-amine	589356: Inhibition of c-Jun	ic50	0.1200	uM
(1S,2S,4S,5R,6S,7S,9R,13R,17S)-4,5-dihydroxy-15-methoxy-2,6,14,17-tetramethyl-10-oxatetracyclo[7.7.1.02,7.013,17]heptadec-14-ene-3,11,16-trione	1178347: Inhibition of AP-1 (unknown origin) by FRET assay	ec50	0.1300	uM
8-cyclopropyl-7-(1-methylpyrazol-4-yl)-N-[4-(3-morpholin-4-yl-1,2,4-triazol-1-yl)phenyl]quinazolin-2-amine	589356: Inhibition of c-Jun	ic50	0.1300	uM
8-methyl-7-(1-methylpyrazol-4-yl)-N-[4-(3-morpholin-4-yl-1,2,4-triazol-1-yl)phenyl]quinazolin-2-amine	589356: Inhibition of c-Jun	ic50	0.1600	uM
N-[3,5-bis(trifluoromethyl)phenyl]-2,4-dichloropyrimidine-5-carboxamide	1178333: Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	ic50	0.2000	uM
3-methyl-1-[[5-(4-methyl-1,3-oxazol-2-yl)-2-thiophen-2-ylpyrimidin-4-yl]amino]pyrrole-2,5-dione	95092: Inhibition of AP-1 (activator protein-1) mediated transcriptional activation in Jurkat T-cells	ic50	0.2000	uM
3-methyl-1-[[5-(2-methyltetrazol-5-yl)-2-thiophen-2-ylpyrimidin-4-yl]amino]pyrrole-2,5-dione	95092: Inhibition of AP-1 (activator protein-1) mediated transcriptional activation in Jurkat T-cells	ic50	0.2000	uM
ethyl 4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-(5-methylthiophen-2-yl)pyrimidine-5-carboxylate	95092: Inhibition of AP-1 (activator protein-1) mediated transcriptional activation in Jurkat T-cells	ic50	0.2000	uM
1-[[5-(4,5-dihydro-1,3-oxazol-2-yl)-2-thiophen-2-ylpyrimidin-4-yl]amino]-3-methylpyrrole-2,5-dione	95092: Inhibition of AP-1 (activator protein-1) mediated transcriptional activation in Jurkat T-cells	ic50	0.2000	uM
ethyl 4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-methylsulfanylpyrimidine-5-carboxylate	95092: Inhibition of AP-1 (activator protein-1) mediated transcriptional activation in Jurkat T-cells	ic50	0.2000	uM
N-[4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-8-(1,3-thiazol-2-yl)quinazolin-2-amine	589356: Inhibition of c-Jun	ic50	0.2000	uM
4-[4-(4-hydroxy-3-methoxyphenyl)-2,3-dimethylbutyl]-2-methoxyphenol	1178344: Inhibition of Fos-Jun dimer formation (unknown origin)	ic50	0.2100	uM
tert-butyl 2-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate	1178333: Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	ic50	0.2100	uM
8-(3-fluoro-4-methoxyphenyl)-N-[4-(3-morpholin-4-yl-1,2,4-triazol-1-yl)phenyl]quinazolin-2-amine	589356: Inhibition of c-Jun	ic50	0.2500	uM
7-(1-methylpyrazol-4-yl)-N-[4-(3-pyridin-2-yl-1,2,4-triazol-1-yl)phenyl]quinazolin-2-amine	589356: Inhibition of c-Jun	ic50	0.2900	uM
N-[3,5-bis(trifluoromethyl)phenyl]-2-chloropyrimidine-5-carboxamide	31747: Concentration required to inhibit activator protein-1(AP-1) mediated transcriptional activation in human Jurkat T-cells	ic50	0.3000	uM
N-[3,5-bis(trifluoromethyl)phenyl]-2-chloro-4-ethylpyrimidine-5-carboxamide	31747: Concentration required to inhibit activator protein-1(AP-1) mediated transcriptional activation in human Jurkat T-cells	ic50	0.3000	uM
ethyl 2-(5-chlorothiophen-2-yl)-4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]pyrimidine-5-carboxylate	95092: Inhibition of AP-1 (activator protein-1) mediated transcriptional activation in Jurkat T-cells	ic50	0.3000	uM
ethyl 2-(3,5-dichlorophenyl)-4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]pyrimidine-5-carboxylate	95092: Inhibition of AP-1 (activator protein-1) mediated transcriptional activation in Jurkat T-cells	ic50	0.3000	uM
3-methyl-1-[[5-(3-methyl-1,2-oxazol-5-yl)-2-thiophen-2-ylpyrimidin-4-yl]amino]pyrrole-2,5-dione	95092: Inhibition of AP-1 (activator protein-1) mediated transcriptional activation in Jurkat T-cells	ic50	0.3000	uM
3-methyl-1-[[5-(5-methyl-1,3,4-oxadiazol-2-yl)-2-thiophen-2-ylpyrimidin-4-yl]amino]pyrrole-2,5-dione	95092: Inhibition of AP-1 (activator protein-1) mediated transcriptional activation in Jurkat T-cells	ic50	0.3000	uM

CTD chemical–gene interactions

524 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
pyrazolanthrone	affects localization, increases phosphorylation, increases expression, increases activity, increases reaction (+5 more)	51
Tetradecanoylphorbol Acetate	increases localization, increases activity, increases expression, affects cotreatment, increases phosphorylation (+7 more)	30
sodium arsenite	affects cotreatment, affects expression, increases localization, decreases reaction, increases expression (+8 more)	27
Arsenic Trioxide	decreases reaction, increases phosphorylation, increases activity, increases reaction, affects response to substance (+7 more)	26
Resveratrol	affects binding, increases reaction, affects cotreatment, decreases expression, decreases phosphorylation (+4 more)	18
Acetylcysteine	increases phosphorylation, affects cotreatment, increases reaction, increases activity, decreases activity (+2 more)	18
Quercetin	affects cotreatment, increases reaction, decreases activity, affects binding, increases expression (+5 more)	16
Estradiol	increases reaction, affects cotreatment, increases expression, increases phosphorylation, affects binding (+4 more)	14
Hydrogen Peroxide	increases localization, decreases reaction, increases expression, increases phosphorylation, increases reaction (+3 more)	14
Cadmium Chloride	increases expression, affects cotreatment, increases reaction, decreases expression, increases abundance (+3 more)	14
Particulate Matter	affects reaction, increases secretion, decreases expression, increases reaction, increases abundance (+5 more)	13
U 0126	decreases reaction, increases expression, increases localization, decreases activity, decreases localization (+5 more)	12
Benzo(a)pyrene	affects activity, increases phosphorylation, increases expression, increases methylation, decreases reaction	12
Lipopolysaccharides	increases activity, affects localization, increases localization, affects cotreatment, increases expression (+5 more)	12
Cisplatin	decreases reaction, affects cotreatment, decreases expression, increases reaction, affects reaction (+3 more)	11
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	increases activity, affects cotreatment, affects localization, decreases reaction, increases phosphorylation (+1 more)	10
Cadmium	increases expression, increases phosphorylation, affects binding, increases reaction, affects cotreatment (+2 more)	9
Bortezomib	decreases expression, increases activity, increases phosphorylation, increases expression, decreases reaction (+1 more)	8
Tetrachlorodibenzodioxin	affects reaction, increases activity, increases reaction, affects localization, decreases reaction (+3 more)	8
Acetaminophen	increases expression, increases phosphorylation, affects cotreatment, increases reaction, decreases reaction (+2 more)	7
Air Pollutants	increases expression, affects cotreatment, decreases expression, increases abundance, affects expression (+1 more)	7
Copper	increases reaction, affects cotreatment, decreases reaction, increases phosphorylation, affects binding (+2 more)	7
Curcumin	increases expression, increases phosphorylation, affects cotreatment, increases activity, decreases activity (+2 more)	7
Tobacco Smoke Pollution	affects expression, decreases expression, increases expression	7
Tretinoin	decreases reaction, affects cotreatment, increases reaction, affects binding, increases phosphorylation (+4 more)	7
Benzene	affects expression, decreases expression, increases expression	6
Doxorubicin	decreases reaction, increases phosphorylation, affects binding, affects cotreatment, increases expression (+3 more)	6
Silicon Dioxide	increases response to substance, decreases reaction, increases phosphorylation, decreases expression, increases reaction (+2 more)	6
Valproic Acid	affects expression, affects cotreatment, increases expression	6
Luteolin	affects reaction, decreases reaction, increases expression, affects localization, affects binding (+6 more)	6

ChEMBL screening assays

88 unique, capped per target: 87 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3223401	Binding	Inhibition of c-FOS/AP1 (unknown origin)	Small-molecule inhibitors of dimeric transcription factors: Antagonism of proteinprotein and proteinDNA interactions — Medchemcomm
CHEMBL705832	Functional	Inhibition of AP-1 (activator protein-1) mediated transcriptional activation in Jurkat T-cells	Novel inhibitors of AP-1 and NF-kappaB mediated gene expression: structure-activity relationship studies of ethyl 4-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)++ +pyrimidi ne-5-carboxylate. — Bioorg Med Chem Lett

Cellosaurus cell lines

14 cell lines: 6 cancer cell line, 4 transformed cell line, 3 embryonic stem cell, 1 telomerase immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1454	NCI-H1092	Cancer cell line	Male
CVCL_A3J5	SEES3-1V human JUN, clone1	Embryonic stem cell	Male
CVCL_A3J6	SEES3-1V human JUN, clone2	Embryonic stem cell	Male
CVCL_A3J7	SEES3-1V human JUN, clone3	Embryonic stem cell	Male
CVCL_B0YG	Abcam HEK293 JUN KO	Transformed cell line	Female
CVCL_C3KA	N/Tert-1 JUN	Telomerase immortalized cell line	Male
CVCL_D7GN	Ubigene HEK293T JUN KO	Transformed cell line	Female
CVCL_D9HT	Ubigene HEK293 JUN KO	Transformed cell line	Female
CVCL_E0FX	Ubigene HeLa JUN KO	Cancer cell line	Female
CVCL_E9C1	HEI-286 F-GFP JUN KO	Transformed cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00092183	PHASE4	COMPLETED	An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
NCT00128778	PHASE4	COMPLETED	Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients
NCT00302120	PHASE4	UNKNOWN	The MONET - Study: MR Mammography of Nonpalpable Breast Tumors
NCT00307606	PHASE4	UNKNOWN	Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma
NCT00370240	PHASE4	COMPLETED	Chlorhydrate of Ropivacaine and Breast Cancer Surgery
NCT00375752	PHASE4	TERMINATED	Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
NCT00575354	PHASE4	COMPLETED	Comparison of Sevoflurane and Isoflurane Anesthesia for Benign Breast Tumor Excision
NCT00604968	PHASE4	TERMINATED	Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)
NCT00616135	PHASE4	COMPLETED	Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy
NCT00649090	PHASE4	COMPLETED	A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer
NCT00779285	PHASE4	TERMINATED	Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)
NCT01176916	PHASE4	COMPLETED	Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
NCT01427400	PHASE4	UNKNOWN	The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction
NCT01849380	PHASE4	UNKNOWN	Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer
NCT01859936	PHASE4	COMPLETED	Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment
NCT01948960	PHASE4	COMPLETED	Influence of Exceptional Patient Characteristics on Everolimus Exposure
NCT01961544	PHASE4	COMPLETED	Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer
NCT01975064	PHASE4	COMPLETED	Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia
NCT02004834	PHASE4	ACTIVE_NOT_RECRUITING	Levobupivacaine and Lidocaine for Paravertebral Block Causes Greater Hemodynamic Oscillations Than Levobupivacaine
NCT02372305	PHASE4	WITHDRAWN	Comparison of FlexHD and Alloderm Outcomes in Breast Reconstructive Surgery
NCT02479347	PHASE4	COMPLETED	Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine
NCT02549677	PHASE4	COMPLETED	Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
NCT02612870	PHASE4	UNKNOWN	Sienna+® Injection Time Study 4 Arms
NCT02627560	PHASE4	COMPLETED	The Effect of Topical Tranexamic Acid on Bleeding and Seroma Formation in After Undergoing Mastectomy
NCT02661932	PHASE4	COMPLETED	Fertility Preservation in Breast Cancer Patients
NCT02781259	PHASE4	UNKNOWN	Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer
NCT02819921	PHASE4	TERMINATED	Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen
NCT03220178	PHASE4	TERMINATED	Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
NCT03583944	PHASE4	COMPLETED	A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer
NCT03586154	PHASE4	COMPLETED	Combined Intra-articular Shoulder Injection and Stellate Ganglion Block in Chronic Post-mastectomy Shoulder Pain
NCT04707196	PHASE4	COMPLETED	A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
NCT04931615	PHASE4	COMPLETED	ARTISS a Single-centre Randomised Control Study
NCT05033769	PHASE4	UNKNOWN	Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer
NCT05036005	PHASE4	UNKNOWN	Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
NCT05452213	PHASE4	RECRUITING	Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
NCT05465031	PHASE4	RECRUITING	Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
NCT05949333	PHASE4	UNKNOWN	Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy
NCT07158164	PHASE4	RECRUITING	DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
NCT07162259	PHASE4	NOT_YET_RECRUITING	Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
NCT00000611	PHASE3	COMPLETED	Women’s Health Initiative (WHI)